Effect of Hemodialysis on Plasma Myeloperoxidase Activity in End Stage Renal Disease Patients

Rao, A. Madhusudhana; Apoorva, R.; Anand, Usha; Anand, C.V.; Venu, G

doi:10.1007/s12291-012-0194-y

Cited by 9 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in contrast with the report of Capeillere-Blandin et al who showed a significantly higher level of myeloperoxidase in ESKD patients on hemodialysis when compared to non-dialysis CKD patients [40]. Increase in myeloperoxidase after hemodialysis [41], its differential regulation by hemodialysis membrane type [42,43], duration of dialysis, and variation in background variables such as anthropometric measures [44], comorbidities and medication use suggest their confounding rules in myeloperoxidase level [45]. The change in 3-ClY is less frequently studied in CKD.…”

Section: Discussionmentioning

confidence: 74%

Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease

et al. 2017

View full text Add to dashboard Cite

Background: The role of myeloperoxidase in chronic kidney disease (CKD) and its association with coronary artery disease (CAD) is controversial. In this study, we compared myeloperoxidase and protein-bound 3-chlorotyrosine (ClY) levels in subjects with varying degrees of CKD and tested their associations with CAD. Methods: From Clinical Phenotyping Resource and Biobank Core, 111 patients were selected from CKD stages 1 to 5. Plasma myeloperoxidase level was measured using enzyme-linked-immunosorbent assay. Plasma protein-bound 3-ClY, a specific product of hypochlorous acid generated by myeloperoxidase was measured by liquid chromatography mass spectrometry. Results: We selected 29, 20, 24, 22, and 16 patients from stages 1 to 5 CKD, respectively. In a sex-adjusted general linear model, mean ± SD of myeloperoxidase levels decreased from 18.1 ± 12.3 pmol in stage 1 to 10.9 ± 4.7 pmol in stage 5 (p = 0.011). In patients with and without CAD, the levels were 19.1 ± 10.1 and 14.8 ± 8.7 pmol (p = 0.036). There was an increase in 3-ClY mean from 0.81 ± 0.36 mmol/mol-tyrosine in stage 1 to 1.42 ± 0.41 mmol/mol-tyrosine in stage 5 (p < 0.001). The mean 3-ClY levels in patients with and without CAD were 1.25 ± 0.44 and 1.04 ± 0.42 mmol/mol-tyrosine (p = 0.023), respectively. C-statistic of ClY when added to myeloperoxidase level to predict CKD stage 5 was 0.86, compared to 0.79 for the myeloperoxidase level alone (p = 0.0097). Conclusion: The myeloperoxidase levels decrease from stages 1 to 5, whereas activity increases. In contrast, both myeloperoxidase and ClY levels rise in the presence of CAD at various stages of CKD. Measuring both plasma myeloperoxidase and 3-CLY levels provide added value to determine the burden of myeloperoxidase-mediated oxidative stress.

show abstract

Section: Discussionmentioning

confidence: 74%

Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Although several Tyr residues are prone to be modifi ed either enzymatically or nonenzymatically by HOCl, we are the fi rst to identify Cl-Tyr residues on apoB-100 at posi tions Tyr 76, 102, 749, 1575, 1687, 1747, 1901, 2341, 2405, 2732, 3653, and 4242 . An increased level of Cl-Tyr, apparently a consequence of high plasma MPO levels ( 50,51 ), was also reported in plasma samples from dialysis patients ( 38,39 ). This observation prompted us to follow PTMs on apoB-100 isolated from plasma of hemodialysis patients who have high plasma MPO-LDL levels ( 25 ) interaction between LDL and MPO that differs from MPO interaction with high-density lipoprotein ( 34 ).…”

Section: Discussionmentioning

confidence: 85%

Impact of myeloperoxidase-LDL interactions on enzyme activity and subsequent posttranslational oxidative modifications of apoB-100

Delporte

Boudjeltia

Noyon

et al. 2014

Journal of Lipid Research

View full text Add to dashboard Cite

Over the past several years, considerable evidence has been obtained in support of the hypothesis that oxidants generated by the heme enzyme myeloperoxidase (MPO, EC1.11.2.2) play a key role in oxidation reaction of the artery wall. The enzyme, abundantly present in neutrophils and, to a lesser extent, in monocytes, is released during infl ammatory activation of immune cells. MPO produces hypochlorous acid (HOCl) by the reaction of hydrogen Abstract Oxidation of LDL by the myeloperoxidase (MPO)-H 2 O 2 -chloride system is a key event in the development of atherosclerosis. The present study aimed at investigating the interaction of MPO with native and modifi ed LDL and at revealing posttranslational modifi cations on apoB-100 (the unique apolipoprotein of LDL) in vitro and in vivo. Using amperometry, we demonstrate that MPO activity increases up to 90% when it is adsorbed at the surface of LDL. This phenomenon is apparently refl ected by local structural changes in MPO observed by circular dichroism. Using MS, we further analyzed in vitro modifi cations of apoB-100 by hypochlorous acid (HOCl) generated by the MPO-H 2 O 2 -chloride system or added as a reagent. A total of 97 peptides containing modifi ed residues could be identifi ed. Furthermore, differences were observed between LDL oxidized by reagent HOCl or HOCl generated by the MPO-H 2 O 2 -chloride system. Finally, LDL was isolated from patients with high cardiovascular risk to confi rm that our in vitro fi ndings are also relevant in vivo. We show that several HOCl-mediated modifi cations of apoB-100 identifi ed in vitro were also present on LDL isolated from patients who have increased levels of plasma MPO and MPO-modifi ed LDL. In conclusion, these data emphasize the specifi city of MPO to oxidize LDL. -Delporte,

show abstract

“…The inhibitory effect of the uremic environment could have contributed to this. In another study conducted on patients with end-stage-renal disease, we observed that the process of hemodialysis itself resulted in a significant rise in plasma MPO levels [25].…”

Section: Mpo and Kidney Diseasementioning

confidence: 87%

Myeloperoxidase: A New Twist to an Old Tale

Anand

2012

Ind J Clin Biochem

Self Cite

View full text Add to dashboard Cite

Effect of Hemodialysis on Plasma Myeloperoxidase Activity in End Stage Renal Disease Patients

Cited by 9 publications

References 22 publications

Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease

Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease

Impact of myeloperoxidase-LDL interactions on enzyme activity and subsequent posttranslational oxidative modifications of apoB-100

Myeloperoxidase: A New Twist to an Old Tale

Contact Info

Product

Resources

About